CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade.
CD16/PD-L1双特异性适体通过募集NK细胞并作为免疫检查点阻断剂用于癌症免疫治疗
期刊:Molecular Therapy-Nucleic Acids
影响因子:6.1
doi:10.1016/j.omtn.2022.01.010
Zheng Aixian, Du Yanlin, Wang Yiru, Zheng Youshi, Ning Zhaoyu, Wu Ming, Zhang Cuilin, Zhang Da, Liu Jingfeng, Liu Xiaolong
